CTY · City Therapeutics, Inc. · Investor Relations
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-10-19 |
City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY) (“City” or “City Therapeutics”), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced the closing of its upsized initial public |
| 2026-10-16 |
City Therapeutics Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY) (“City” or “City Therapeutics”), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced the pricing of its upsized initial public |
| 2026-08-11 |
City Therapeutics Appoints Keith Regnante, MBA, as Chief Financial Officer and Mary Beth DeLena, J.D., as Chief Legal Officer
CAMBRIDGE, Mass.--( BUSINESS WIRE)--City Therapeutics, Inc. (City), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced the appointments of Keith Regnante, MBA, as Chief Financial Officer, and Mary Beth DeLena, J.D., as |
| 2026-06-08 |
City Therapeutics Announces $99.5 Million Series B Financing to Advance Next-Generation RNAi Therapeutics
Viking Global Investors and Sofinnova Investments join a strong syndicate of existing investors including ARCH Venture Partners, Fidelity Management & Research Company and Invus Proceeds to accelerate the company’s RNAi engineering platform and pipeline, including ongoing Phase 1 clinical trial of |
| 2026-05-06 |
City Therapeutics Presents Preclinical Data on Next-Generation Investigational RNAi Therapy CITY-RBP4 for Treatment of Stargardt Disease at ARVO 2026 Annual Meeting
Data demonstrate potent, durable RNAi-mediated silencing of retinol binding protein 4 (RBP4) with reduced toxic retinoid accumulation, a key driver of the rare inherited retinal disease CAMBRIDGE, MA, May 6, 2026 – City Therapeutics, Inc., a biopharmaceutical company leading the future of RNA |
| 2025-11-10 |
City Therapeutics Announces Submission of Clinical Trial Application for CITY-FXI, an Investigational RNAi Therapeutic for the Treatment of Thromboembolic Diseases
Company plans to initiate a Phase 1 study in early 2026 with initial human data expected late 2026 Company’s first clinical-stage program headlines a diverse and novel pipeline poised to deliver 1-2 new investigational drugs into the clinic annually CAMBRIDGE, MA, November 10, 2025 – City |
| 2025-05-27 | Biogen taps City Therapeutics in RNAi deal worth up to $1B |
| 2025-05-27 |
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
Collaboration leverages City Therapeutics’ next-generation RNAi engineering technologies and Biogen’s extensive drug development expertise CAMBRIDGE, MA, May 27, 2025 – Biogen Inc. (Nasdaq: BIIB) and City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA |
| 2025-04-17 |
City Therapeutics Expands Executive Team and Board of Directors
Baisong Mei, M.D., Ph.D., appointed as chief medical officer and Anna O’Driscoll as chief human resources officer Sara Nochur, Ph.D., appointed as independent member of the company’s board of directors CAMBRIDGE, MA, April 17, 2025 – City Therapeutics, Inc., a privately held biopharmaceutical |
| 2025-02-11 | John Maraganore shares his take on biotech in 2025 and discusses the science behind his recently launched RNAi company, City Therapeutics |
Source: https://investors.citytx.com/